News & Events

  • Broken String Biosciences and BioLizard to Develop AI for Faster, Safer Gene Editing

    Broken String Biosciences and BioLizard to Develop AI for Faster, Safer Gene Editing

    Share BOSTON & CHICAGO & CAMBRIDGE, England–(BUSINESS WIRE)–Broken String Biosciences, a leader in advancing gene editing safety, and BioLizard, an expert in scientific data analytics and AI, today announced the development of SafeGuide, an AI tool for selecting safer, better guide RNAs (gRNA), the gene editing element that tells tools like CRISPR where to repair…

    Read more

  • AI Meets Gene Editing: the Path to Plug-and-Play Drug Development

    AI Meets Gene Editing: the Path to Plug-and-Play Drug Development

    AI is no panacea, but it can have a role in turning artisanal, trial-and-error drug development into a rapid, cost-effective, data-driven process. By Felix Dobbs on July 10, 2025 8:58 am via MedCity News A generation ago, writing a piece like this about using artificial intelligence to develop genome-editing medicines would have sounded like a Star Trek plotline. But…

    Read more

  • Broken String Biosciences Launches Catalyst Program to Shorten Gene Editing Therapy Development by Months

    Broken String Biosciences Launches Catalyst Program to Shorten Gene Editing Therapy Development by Months

    BOSTON, MA and Cambridge, UK, February 6, 2025 – Broken String Biosciences (“Broken String”), a leader in advancing gene editing safety, today opened its Catalyst Early Access Program (EAP) for developers of gene-edited therapies that allow for the detection of on- and off-target edits at high resolution, in days, in their own labs. The program…

    Read more

  • Broken String Biosciences appoints Laurence Reid and Brad Crutchfield to its Board of Directors 

    Broken String Biosciences appoints Laurence Reid and Brad Crutchfield to its Board of Directors 

    Cambridge, UK, 23 September 2024: Broken String Biosciences (“Broken String”), a genomics company enabling development of the next generation of more precise, safe, and effective cell and gene therapies, today announced the appointments of Laurence Reid, PhD, as Chairman, and Brad Crutchfield as Non-Executive Director (NED) of its Board of Directors.  Bringing extensive commercial and leadership expertise to the Board, Laurence…

    Read more

  • Broken String Biosciences appoints Steve Becker as Chief Commercial Officer 

    Broken String Biosciences appoints Steve Becker as Chief Commercial Officer 

    Appointment brings extensive experience to lead commercial operations and accelerate growth in key global markets Cambridge, UK, 24 July 2024: Broken String Biosciences (“Broken String”), a genomics company driving development of the next generation of more precise, safe, and effective cell and gene therapies, today announced it has appointed Steve Becker as Chief Commercial Officer. An experienced global life sciences executive,…

    Read more

  • Broken String Biosciences and the Francis Crick Institute collaborate to advance ALS research

    Broken String Biosciences and the Francis Crick Institute collaborate to advance ALS research

    Partnership to expand applications of DNA break-mapping technology and advance understanding of genomic instability in development of the neurodegenerative disease amyotrophic lateral sclerosis Cambridge, UK,  7 May 2024: Broken String Biosciences (“Broken String”), a genomics company driving development of the next generation of more precise, safe, and effective cell and gene therapies, today announced it has entered a research collaboration with…

    Read more

  • Broken String Biosciences’ INDUCE-seq platform demonstrates impact of structural DNA changes on specificity of CRISPR-Cas9 gene editing 

    Broken String Biosciences’ INDUCE-seq platform demonstrates impact of structural DNA changes on specificity of CRISPR-Cas9 gene editing 

    Cambridge, UK, 18 October 2023: Broken String Biosciences (“Broken String”), a genomics company building a technology platform to drive the development of cell and gene therapies that are safer by design, today announced that its INDUCE-seq™ DNA break-mapping technology had been used in a peer-reviewed research paper to characterize off-target effects of CRISPR-Cas9 gene editing…

    Read more

  • Broken String Biosciences Closes $15M Series A Funding Round

    Broken String Biosciences Closes $15M Series A Funding Round

    Cambridge, UK, 18 September 2023: Broken String Biosciences (“Broken String”), a genomics company building a technology platform to drive the development of cell and gene therapies that are safer by design, today announced that it has closed a $15 million Series A investment round, co-led by Illumina Ventures and Mérieux Equity Partners, with contributions from…

    Read more